24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Corporate
Appointments
Tech Gateways
@Finance
Ctech Testimonials
Projects
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Epitomee
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
11:38
SpaceX's IPO was never about the numbers
11:09
Why did the White House pull Anthropic's most powerful AI model?
09:10
Inside the IDF's cyber war simulator
17:41
Facebook, Instagram and Messenger suffer widespread outage
More stories
Buzz
Most popular
Daily
Weekly
1
More than 50 years after its debut, Israel's Kfir fighter jet gets a new lease on life
2
Echo: “Employees have become very good at identifying performative culture”
3
How Israel’s AI surveillance breakthrough in Iran is reshaping global intelligence
4
Former Microsoft and Tesla security leaders emerge with $35 million for Pi
5
Rylo raises $85 million at $500 million valuation, targets $1 billion revenue by 2028
More news
Epitomee
4 stories about Epitomee
Epitomee surges 200% in two days on FDA approval for weight loss pill
16.09.24
|
Adiel Eithan Mustaki
Investors are hopeful, but the company must now face an uphill battle in a crowded market.
Weight loss pill maker Epitomee’s stock sinks 70% after Nestlé cancels agreement
04.12.23
|
Adiel Eithan Mustaki
The Swiss conglomerate notified Epitomee that it has decided not to market its product as the clinical trial results measuring the disparity in the weight loss rate between patients who took the pill and the control group did not reach the previously agreed upon success level
Weight loss pill success sparks stock surge at Epitomee Medical
04.09.23
|
Adiel Eithan Mustaki
The company, which has not yet published the full results of its study, plans to seek FDA approval via the 510(k) pathway
Weight-Loss Pill Developer Epitomee Raises $8 Million
10.04.19
|
CTech
Epitomee develops an orally administered capsule that affects the stomach through mechanosensory stimulation, encouraging prolonged gastric emptying and giving patients the sensation of being full